Ratio of cyclin-dependent kinase 1 (CDK1) activity to CDK2 activity after ex vivo paclitaxel treatment predicts response to paclitaxel in human breast cancer

被引：0
|
作者：
Kim, S. J.
Taguchi, T.
Tamaki, Y.
Tsukamoto, F.
Akazawa, K.
Ueno, N. T.
Hortobagyi, G. N.
Nakayama, S.
Torikoshi, Y.
Gohda, K.
Ishihara, H.
Noguchi, S.
机构：
[1] Osaka Univ, Grad Sch Med, Osaka, Japan
[2] Osaka Koseinenkin Hosp, Osaka, Japan
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Sysmex Corp, Kobe, Hyogo, Japan
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：366S / 366S
页数：1
相关论文
共 50 条
  • [21] Use of CDK1 and CDK2 activity to predict renal cell cancer recurrence
    Hongo, F.
    Takaha, N.
    Kimura, Y.
    Nakamura, T.
    Mikami, K.
    Nakayama, S.
    Shibayama, M.
    Ishihara, H.
    Sakai, T.
    Miki, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] CDK1 AND CDK2 ACTIVITY IS A STRONG PREDICTOR OF RENAL CELL CANCER RECURRENCE
    Hongo, Fumiya
    Takaha, Natsuki
    Kimura, Yasunori
    Nakamura, Terukazu
    Mikami, Kazuya
    Nakayama, Satoshi
    Matsushima, Tomoko
    Ishihara, Hideaki
    Sakai, Toshiyuki
    Miki, Tsuneharu
    JOURNAL OF UROLOGY, 2011, 185 (04): : E390 - E390
  • [23] Understanding biological rationale for specific activity of CDK1 and CDK2 as a prognostic marker of breast cancer recurrence
    Shibayama, Masaki
    Numada, Shigehiro
    Matsushima, Tomoko
    Nakayama, Satoshi
    Kiniwa, Tadashi
    Harada, Amane
    Kim, Seung
    Shimomura, Atsushi
    Noguchi, Shinzaburo
    Ishihara, Hideki
    CANCER RESEARCH, 2009, 69
  • [24] Inhibition of cyclin-dependent kinase 1 (cdk1) by indirubin derivatives in human tumor cells.
    Marko, D
    Schätzle, S
    Eisenbrand, G
    CLINICAL CANCER RESEARCH, 1999, 5 : 3756S - 3756S
  • [25] Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1
    Casagrande, F
    Darbon, JM
    BIOCHEMICAL PHARMACOLOGY, 2001, 61 (10) : 1205 - 1215
  • [26] Cyclin-dependent kinase-2 (Cdk2) forms an inactive complex with cyclin D1 since Cdk2 associated with cyclin D1 is not phosphorylated by Cdk7-cyclin-H
    Higashi, H
    SuzukiTakahashi, I
    Saitoh, S
    Segawa, K
    Taya, Y
    Okuyama, A
    Nishimura, S
    Kitagawa, M
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 1996, 237 (02): : 460 - 467
  • [27] Paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity
    Schultz, C
    Link, A
    Leost, M
    Zaharevitz, DW
    Gussio, R
    Sausville, EA
    Meijer, L
    Kunick, C
    JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (15) : 2909 - 2919
  • [28] The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity
    Alessi, F
    Quarta, S
    Savio, M
    Riva, F
    Rossi, L
    Stivala, LA
    Scovassi, AI
    Meijer, L
    Prosperi, E
    EXPERIMENTAL CELL RESEARCH, 1998, 245 (01) : 8 - 18
  • [29] Prospective evaluation of changes in CDK activity by ex vivo paclitaxel treatment to predict primary breast tumor response to taxanes
    Ueno, N. T.
    Symmans, F.
    Sugimoto, T.
    Pusztai, L.
    Sanchez, L.
    Lara, J.
    Sudo, T.
    Matsushima, T.
    Yoshida, T.
    Ishihara, H.
    Hortobagyi, G. N.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2007, 22 (01): : 82 - 83
  • [30] Binding of HTm4 to cyclin-dependent kinase (cdk)-associated phosphatase (KAP)•cdk2•cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP dephosphorylation of cdk2
    Chinami, M
    Yano, Y
    Yang, X
    Salahuddin, S
    Moriyama, K
    Shiroishi, M
    Turner, H
    Shirakawa, T
    Adra, CN
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (17) : 17235 - 17242
12345